Nothing Special   »   [go: up one dir, main page]

SE9802402D0 - Method of diagnosing cardiovascular disease and early atherosclerosis - Google Patents

Method of diagnosing cardiovascular disease and early atherosclerosis

Info

Publication number
SE9802402D0
SE9802402D0 SE9802402A SE9802402A SE9802402D0 SE 9802402 D0 SE9802402 D0 SE 9802402D0 SE 9802402 A SE9802402 A SE 9802402A SE 9802402 A SE9802402 A SE 9802402A SE 9802402 D0 SE9802402 D0 SE 9802402D0
Authority
SE
Sweden
Prior art keywords
cardiovascular disease
diagnosing cardiovascular
early atherosclerosis
human
present
Prior art date
Application number
SE9802402A
Other languages
English (en)
Inventor
Johan Frostegaard
Original Assignee
Karolinska Innovations Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karolinska Innovations Ab filed Critical Karolinska Innovations Ab
Priority to SE9802402A priority Critical patent/SE9802402D0/sv
Publication of SE9802402D0 publication Critical patent/SE9802402D0/sv
Priority to AT99933432T priority patent/ATE250228T1/de
Priority to US09/720,967 priority patent/US6780605B1/en
Priority to DK99933432T priority patent/DK1095271T3/da
Priority to PCT/SE1999/001208 priority patent/WO2000002046A1/en
Priority to AU49489/99A priority patent/AU4948999A/en
Priority to ES99933432T priority patent/ES2205853T3/es
Priority to EP99933432A priority patent/EP1095271B1/en
Priority to DE69911417T priority patent/DE69911417T2/de
Priority to US10/814,194 priority patent/US20040185515A1/en
Priority to US10/814,195 priority patent/US20040185516A1/en
Priority to US10/814,125 priority patent/US7662577B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SE9802402A 1998-07-03 1998-07-03 Method of diagnosing cardiovascular disease and early atherosclerosis SE9802402D0 (sv)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SE9802402A SE9802402D0 (sv) 1998-07-03 1998-07-03 Method of diagnosing cardiovascular disease and early atherosclerosis
DE69911417T DE69911417T2 (de) 1998-07-03 1999-07-02 Verfahren zur diagnose von gefässerkrankungen und früher atheriosklerose
PCT/SE1999/001208 WO2000002046A1 (en) 1998-07-03 1999-07-02 Method of diagnosing cardiovascular disease and early atherosclerosis
US09/720,967 US6780605B1 (en) 1998-07-03 1999-07-02 Method of diagnosing cardiovascular disease and early atherosclerosis
DK99933432T DK1095271T3 (da) 1998-07-03 1999-07-02 Fremgangsmåde til diagnose af hjertekar-sygdomme og tidlig aterosklerose
AT99933432T ATE250228T1 (de) 1998-07-03 1999-07-02 Verfahren zur diagnose von gefässerkrankungen und früher atheriosklerose
AU49489/99A AU4948999A (en) 1998-07-03 1999-07-02 Method of diagnosing cardiovascular disease and early atherosclerosis
ES99933432T ES2205853T3 (es) 1998-07-03 1999-07-02 Metodo para diagnosticar la enfermedad cardiovascular y la aterosclerosis precoz.
EP99933432A EP1095271B1 (en) 1998-07-03 1999-07-02 Method of diagnosing cardiovascular disease and early atherosclerosis
US10/814,194 US20040185515A1 (en) 1998-07-03 2004-04-01 Method of diagnosing spontaneous abortion
US10/814,195 US20040185516A1 (en) 1998-07-03 2004-04-01 Kit for diagnosing cadiovascular disease and early atherosclerosis
US10/814,125 US7662577B2 (en) 1998-07-03 2004-04-01 Method of diagnosing cardiovascular disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9802402A SE9802402D0 (sv) 1998-07-03 1998-07-03 Method of diagnosing cardiovascular disease and early atherosclerosis

Publications (1)

Publication Number Publication Date
SE9802402D0 true SE9802402D0 (sv) 1998-07-03

Family

ID=20411962

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9802402A SE9802402D0 (sv) 1998-07-03 1998-07-03 Method of diagnosing cardiovascular disease and early atherosclerosis

Country Status (2)

Country Link
US (4) US6780605B1 (sv)
SE (1) SE9802402D0 (sv)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7569674B2 (en) * 1998-05-04 2009-08-04 Innexus Biotechnology International Limited Autophilic antibodies
US20050033033A1 (en) * 1998-05-04 2005-02-10 Heinz Kohler Trans-membrane-antibody induced inhibition of apoptosis
US20040185039A1 (en) * 2002-08-30 2004-09-23 Heinz Kohler Therapeutic applications of noncovalent dimerizing antibodies
US20090208418A1 (en) * 2005-04-29 2009-08-20 Innexus Biotechnology Internaltional Ltd. Superantibody synthesis and use in detection, prevention and treatment of disease
PL1735349T3 (pl) 2004-04-15 2011-03-31 Athera Biotechnologies Ab Sposób oceny ryzyka niedokrwiennego schorzenia układu sercowo-naczyniowego za pomocą koniugatów fosforylocholiny
CN101253409A (zh) * 2005-08-02 2008-08-27 埃克斯生物科技公司 使用IL-1α自身抗体诊断、治疗和预防血管疾病
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
EP2021033B1 (en) * 2006-05-15 2012-03-28 XBiotech, Inc Il-1-alpha for use in a method of treatment of atherosclerotic plaques.
US20100040574A1 (en) * 2006-05-22 2010-02-18 Xbiotech Inc. TREATMENT OF CANCER WITH ANTI-IL-1alpha ANTIBODIES
US7935498B2 (en) * 2006-07-07 2011-05-03 Siemens Healthcare Diagnostics Inc. Methods for identifying patients with increased risk of an adverse cardiovascular event
EP2217280A1 (en) * 2007-10-30 2010-08-18 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for cardiovascular disease
NZ590033A (en) * 2008-05-30 2011-08-26 Xbiotech Inc Interleukin-1alpha antibodies and methods of use
CN102209557A (zh) * 2008-09-12 2011-10-05 埃克斯生物科技公司 靶向病原性单核细胞
KR102167261B1 (ko) 2010-06-18 2020-10-20 엑스바이오테크, 인크. 관절염 치료
RU2679119C2 (ru) 2010-08-23 2019-02-06 ИксБиотеч, Инк. Лечение неопластических заболеваний
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
TR201909072T4 (tr) 2011-08-09 2019-08-21 Athera Biotechnologies Ab Fosforilkoline karşı yeni antikorlar.
JP6277126B2 (ja) 2011-08-09 2018-02-07 アセラ・バイオテクノロジーズ・アーベー ホスホリルコリン（ｐｃ）および／またはｐｃコンジュゲートに結合する抗体
KR102039198B1 (ko) 2011-09-23 2019-10-31 엑스바이오테크, 인크. 악액질 치료법
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
AU2018220862A1 (en) 2017-02-16 2019-08-29 Janssen Biotech, Inc. Treatment of hidradenitis suppurativa
WO2021134505A1 (zh) * 2019-12-31 2021-07-08 同济大学 一种用于预测早期流产风险的试剂盒及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US5061626A (en) * 1986-03-24 1991-10-29 University Of Sydney Antigenic anarogues of platelet activating factor
US4879285A (en) * 1986-08-22 1989-11-07 Royal North Shore Hospital And Area Health Service Fertility control
US5731208A (en) 1996-09-09 1998-03-24 Washington University Method of detecting conditions indicative of atherosclerosis

Also Published As

Publication number Publication date
US20040185516A1 (en) 2004-09-23
US6780605B1 (en) 2004-08-24
US20040185515A1 (en) 2004-09-23
US20040185514A1 (en) 2004-09-23
US7662577B2 (en) 2010-02-16

Similar Documents

Publication Publication Date Title
SE9802402D0 (sv) Method of diagnosing cardiovascular disease and early atherosclerosis
DE69937368D1 (de) Nachweis von erkrankungen der nieren und behandlung
DE69836272D1 (de) Versuchsanordnung zur bestimmung von analyten in körperflüssigkeiten
MX9601324A (es) Biosensor.
DE69603491D1 (de) Reagenz und verfahren zur differentiellen bestimmung von leukocyten im blut
ES2061422T3 (es) Metodos para detectar la resorcion osea in vivo.
DE69618447D1 (de) Frühzeitiger nachweis von prostatakrebs (cap) durch bestimmung des konzentrationsverhältnisses zwischen prostataspezifischem antigen (psa) und menschlichem drüsenkallikrein (hgk-1)
AU4948999A (en) Method of diagnosing cardiovascular disease and early atherosclerosis
DE59208032D1 (de) Funktioneller Test und Reagenz zur Bestimmung von Fibrinogen
DE3779704D1 (de) Verfahren und testkit zur bestimmung freier wirkstoffe in biologischen fluessigkeiten.
ATE258310T1 (de) Testverfahren für collagenpeptid
DE3888998D1 (de) Verfahren zur Bestimmung eines Antikörpers in menschlichen Körperflüssigkeiten.
ES2142070T3 (es) Utilizacion de un complejo ficobiliproteina-peptido de enlace como trazador fluorescente.
DE3850249D1 (de) Nachweis von analyt in partikel enthaltenden proben.
IT1241154B (it) Metodo e composizione reagente per la determinazione dell'alanina amminotrasferasi e dell'antigene hbsag in uno stesso campione biologico
IT8921788A0 (it) Reattivo utile per la rilevazione e la determinazione quantitativa dei leucociti in fluidi biologici.
DK0791073T3 (da) Analysemetode
DE3765147D1 (de) Verfahren und reagenz zur bestimmung von gesamt-bilirubin.
ATE173830T1 (de) Verfahren zur bestimmung der quantität extrazellulärer bpi in körperflüssigkeiten
DE69426028D1 (de) Reagenz für die enzymatische Bestimmung des Bikarbonatgehalts in Blutserum
ATE223055T1 (de) Verfahren zur diagnose von chlamydia in einer biologischen extrazellulären flüssigkeit
DE69132144D1 (de) Menschliche phospholipase aktivierender proteinteil
DE60212998D1 (de) Gesamtcystein-assay
DE68911574D1 (de) Reagenzsystem zur Bestimmung des Komplexes des menschlichen Plasminogenaktivator-Inhibitors und des menschlichen Gewebeplasminogenaktivators und Testsatz dafür.
DE59609166D1 (de) Bestimmung der endständigen sialinsäurereste des human-transferrin-moleküls